WMFC Members, we received the following update on the WhiMSICAL program. Your participation is highly encouraged. Thank you for the support!
Waldendstom’s Macroglobulinemia Study Involving CArt-WheeL
a world-first, ethically-approved, comprehensive survey of patient –… Continue reading
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity.
Diagnosis: Presence… Continue reading
Please find below a list of clinical trials available. Please click on Clinical Trial Number to link to more information.
IMBRUVICA® is an oral, once-daily, single-agent therapy associated with a durable response in patients with this rare B-cell lymphoma
TORONTO, May 12, 2016 /CNW/ – Janssen Inc. announced today that Health Canada has issued… Continue reading
If you have Waldenstrom’s Macroglobulinemia (WM) or you are a caregiver of a patient with WM, you can help by completing the surveys.
Lymphoma Canada, in partnership with the Canadian Organization… Continue reading